240 E. GRAND AVE., SOUTH SAN FRANCISCO, CA
Investor Presentation
Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates
ORIC Pharmaceuticals Enters $200 Million Sales Agreement with Jefferies
Financial Results, Press Release
Financial Results, Costs of Shutting Down or Selling Parts of the Business
Shareholder votes
FY 2024
Q3
Q2
Q1
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Correspondence
Submission Upload